|
Name |
(1S,9R,14E)-14-(1H-imidazol-5-ylmethylidene)-2,11-dimethoxy-9-(2-methylbut-3-en-2-yl)-2,13,16-triazatetracyclo[7.7.0.01,13.03,8]hexadeca-3,5,7,10-tetraene-12,15-dione
|
Molecular Formula | C24H25N5O4 | |
IUPAC Name* |
(1S,9R,14E)-14-(1H-imidazol-5-ylmethylidene)-2,11-dimethoxy-9-(2-methylbut-3-en-2-yl)-2,13,16-triazatetracyclo[7.7.0.01,13.03,8]hexadeca-3,5,7,10-tetraene-12,15-dione
|
|
SMILES |
CC(C)(C=C)[C@@]12C=C(C(=O)N\3[C@]1(NC(=O)/C3=C\C4=CN=CN4)N(C5=CC=CC=C25)OC)OC
|
|
InChI |
InChI=1S/C24H25N5O4/c1-6-22(2,3)23-12-19(32-4)21(31)28-18(11-15-13-25-14-26-15)20(30)27-24(23,28)29(33-5)17-10-8-7-9-16(17)23/h6-14H,1H2,2-5H3,(H,25,26)(H,27,30)/b18-11+/t23-,24-/m0/s1
|
|
InChIKey |
SOHAVULMGIITDH-ZXPSTKSJSA-N
|
|
Synonyms |
Oxaline; 55623-37-5; CHEMBL4443890; Q63399742; (3E,7aR,12aS)-3-[(1H-imidazol-4-yl)methylidene]-6,12-dimethoxy-7a-(2-methylbut-3-en-2-yl)-7a,12-dihydro-1H,5H-imidazo[1
|
|
CAS | NA | |
PubChem CID | 70698220 | |
ChEMBL ID | CHEMBL4443890 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 447.5 | ALogp: | 3.4 |
HBD: | 2 | HBA: | 6 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 99.8 | Aromatic Rings: | 5 |
Heavy Atoms: | 33 | QED Weighted: | 0.539 |
Caco-2 Permeability: | -4.992 | MDCK Permeability: | 0.00002750 |
Pgp-inhibitor: | 1 | Pgp-substrate: | 0.011 |
Human Intestinal Absorption (HIA): | 0.689 | 20% Bioavailability (F20%): | 0.98 |
30% Bioavailability (F30%): | 0.987 |
Blood-Brain-Barrier Penetration (BBB): | 0.86 | Plasma Protein Binding (PPB): | 73.32% |
Volume Distribution (VD): | 0.881 | Fu: | 18.49% |
CYP1A2-inhibitor: | 0.079 | CYP1A2-substrate: | 0.768 |
CYP2C19-inhibitor: | 0.915 | CYP2C19-substrate: | 0.815 |
CYP2C9-inhibitor: | 0.913 | CYP2C9-substrate: | 0.486 |
CYP2D6-inhibitor: | 0.802 | CYP2D6-substrate: | 0.057 |
CYP3A4-inhibitor: | 0.976 | CYP3A4-substrate: | 0.956 |
Clearance (CL): | 7.338 | Half-life (T1/2): | 0.426 |
hERG Blockers: | 0 | Human Hepatotoxicity (H-HT): | 0.77 |
Drug-inuced Liver Injury (DILI): | 0.985 | AMES Toxicity: | 0.817 |
Rat Oral Acute Toxicity: | 0.796 | Maximum Recommended Daily Dose: | 0.711 |
Skin Sensitization: | 0.928 | Carcinogencity: | 0.686 |
Eye Corrosion: | 0.005 | Eye Irritation: | 0.059 |
Respiratory Toxicity: | 0.853 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004492 | 0.676 | D01PZD | 0.233 | ||||
ENC004495 | 0.517 | D0W7WC | 0.232 | ||||
ENC004496 | 0.517 | D0E3WQ | 0.230 | ||||
ENC004494 | 0.507 | D06GKN | 0.230 | ||||
ENC004493 | 0.500 | D0OB1J | 0.227 | ||||
ENC004497 | 0.391 | D09WKB | 0.227 | ||||
ENC006112 | 0.346 | D01WLC | 0.227 | ||||
ENC002459 | 0.336 | D09NIA | 0.226 | ||||
ENC003246 | 0.328 | D0E6OC | 0.223 | ||||
ENC003221 | 0.328 | D09LZT | 0.217 |